Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

[Changes of WT1 mRNA expression level in patients with myelodysplastic syndromes after hypomethylating agents and its prognostic significance].

Zhang HY, Geng SX, Li MM, Lai PL, Deng CX, Lu ZS, Huang X, Wang YL, Weng JY, Du X.

Zhonghua Xue Ye Xue Za Zhi. 2019 May 14;40(5):417-421. doi: 10.3760/cma.j.issn.0253-2727.2019.05.013. Chinese.

PMID:
31207708
2.

[Expression of WT1 and PRAME gene in bone marrow and peripheral blood samples of patients with myelodysplastic syndrome].

Lu D, Qin YZ, Li LD, Shi HX, Lai YY, Liu YR.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Apr;22(2):370-6. doi: 10.7534/j.issn.1009-2137.2014.02.019. Chinese.

PMID:
24763007
3.

Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes.

Cilloni D, Gottardi E, Messa F, Fava M, Scaravaglio P, Bertini M, Girotto M, Marinone C, Ferrero D, Gallamini A, Levis A, Saglio G; Piedmont Study Group on Myleodysplastic Syndromes.

J Clin Oncol. 2003 May 15;21(10):1988-95.

PMID:
12743153
4.

[Clinical significance of the Wilms' tumor 1 mRNA expression in childhood myelodysplastic syndrome].

Cheng YF, Zhang LP, Liu YR, Qin YZ, Wu J, Liu GL.

Zhonghua Xue Ye Xue Za Zhi. 2012 Jul;33(7):536-40. Chinese.

PMID:
22967413
5.

The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes.

Tamaki H, Ogawa H, Ohyashiki K, Ohyashiki JH, Iwama H, Inoue K, Soma T, Oka Y, Tatekawa T, Oji Y, Tsuboi A, Kim EH, Kawakami M, Fuchigami K, Tomonaga M, Toyama K, Aozasa K, Kishimoto T, Sugiyama H.

Leukemia. 1999 Mar;13(3):393-9.

PMID:
10086730
6.

Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes.

Kobayashi S, Ueda Y, Nannya Y, Shibayama H, Tamura H, Ogata K, Akatsuka Y, Usuki K, Ito Y, Okada M, Suzuki T, Hata T, Matsuda A, Tohyama K, Kakumoto K, Koga D, Mitani K, Naoe T, Sugiyama H, Takaku F.

Cancer Biomark. 2016 Mar 31;17(1):21-32. doi: 10.3233/CBM-160612.

PMID:
27062571
7.

Biomarkers of angiogenesis as prognostic factors in myelodysplastic syndrome patients treated with hypomethylating agents.

Kim CK, Han DH, Ji YS, Lee MS, Min CW, Park SK, Kim SH, Yun J, Kim HJ, Kim KH, Lee KT, Won JH, Hong DS, Kim HK.

Leuk Res. 2016 Nov;50:21-28. doi: 10.1016/j.leukres.2016.08.012. Epub 2016 Sep 5.

PMID:
27639703
8.

Wilms Tumor 1 (WT1) mRNA Expression Level at Diagnosis Is a Significant Prognostic Marker in Elderly Patients with Myelodysplastic Syndrome.

Nagasaki J, Aoyama Y, Hino M, Ido K, Ichihara H, Manabe M, Ohta T, Mugitani A.

Acta Haematol. 2017;137(1):32-39. doi: 10.1159/000452732. Epub 2016 Nov 19.

PMID:
27866185
9.

Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes.

Ueda Y, Mizutani C, Nannya Y, Kurokawa M, Kobayashi S, Takeuchi J, Tamura H, Ogata K, Dan K, Shibayama H, Kanakura Y, Niimi K, Sasaki K, Watanabe M, Emi N, Teramura M, Motoji T, Kida M, Usuki K, Takada S, Sakura T, Ito Y, Ohyashiki K, Ogawa H, Suzuki T, Ozawa K, Imai K, Kasai M, Hata T, Miyazaki Y, Morita Y, Kanamaru A, Matsuda A, Tohyama K, Koga D, Tamaki H, Mitani K, Naoe T, Sugiyama H, Takaku F.

Leuk Lymphoma. 2013 Jul;54(7):1450-8. doi: 10.3109/10428194.2012.745074. Epub 2012 Nov 26.

PMID:
23110324
10.

[Expression of WT1 gene in patients with myelodysplastic syndrome and acute leukemia].

Lu Y, Jin J, Xu WL.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2004 Aug;12(4):464-6. Chinese.

PMID:
15363132
11.

[WT1 gene expression in myelodysplastic syndrome and its clinical implication].

Huang J, Jin J, Xu WL.

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2006 Mar;35(2):132-5. Chinese.

PMID:
16610077
12.

Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival.

Santamaría C, Ramos F, Puig N, Barragán E, de Paz R, Pedro C, Insunza A, Tormo M, Del Cañizo C, Diez-Campelo M, Xicoy B, Salido E, Sánchez del Real J, Hernández M, Chillón C, Sanz GF, García-Sanz R, San Miguel JF, González M.

Ann Hematol. 2012 Dec;91(12):1887-95. doi: 10.1007/s00277-012-1538-7. Epub 2012 Aug 9.

PMID:
22875062
13.

Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.

Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, Daver N, O'Brien S, Steensma DP, Sekeres MA, Gore SD, Dezern A, Roboz GJ, List AF, Kantarjian HM, Komrokji RS.

Cancer. 2015 Mar 15;121(6):876-82. doi: 10.1002/cncr.29145. Epub 2014 Nov 19.

14.

[Wilms' tumor-1 gene expression in myelodysplastic syndrome and its changes in the process of myelodysplastic syndrome transforming into acute leukemia].

Yang JK, Li JL, Li ZG, Li ZG, Liu PJ, Li JY, Lü HR, Deng Q, Lin XM, Cao JN.

Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2003 Sep;15(9):557-9. Chinese.

PMID:
12971856
15.

High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome.

Bergmann L, Miething C, Maurer U, Brieger J, Karakas T, Weidmann E, Hoelzer D.

Blood. 1997 Aug 1;90(3):1217-25.

16.

Prognostic significance of WT1 mRNA and anti-WT1 antibody levels in peripheral blood in patients with myelodysplastic syndromes.

Tamura H, Dan K, Yokose N, Iwakiri R, Ohta M, Sakamaki H, Tohyama K, Kondo A, Hyodo H, Nakamura K, Yamashita T, Elisseeva OA, Oka Y, Oji Y, Sugiyama H, Ogata K.

Leuk Res. 2010 Aug;34(8):986-90. doi: 10.1016/j.leukres.2009.11.029. Epub 2010 Jan 19.

PMID:
20031209
17.

Associations between the peripheral blood Wilms tumor gene 1 level and both bone marrow blast cells and the prognosis in patients with myelodysplastic syndrome.

Mashima K, Ikeda T, Toda Y, Ito S, Umino K, Minakata D, Nakano H, Morita K, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Yamamoto C, Fujiwara S, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y.

Leuk Lymphoma. 2019 Mar;60(3):703-710. doi: 10.1080/10428194.2018.1504940. Epub 2018 Sep 6.

PMID:
30188227
18.

The level of bone marrow WT1 message is a useful marker to differentiate myelodysplastic syndromes with low blast percentage from cytopenia due to other reasons.

Baba M, Hata T, Tsushima H, Mori S, Sasaki D, Turuta K, Hasegawa H, Ando K, Sawayama Y, Imanishi D, Taguchi J, Yanagihara K, Tomonaga M, Kamihira S, Miyazaki Y.

Intern Med. 2015;54(5):445-51. doi: 10.2169/internalmedicine.54.3123. Epub 2015 Jan 15.

19.

Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes.

Minetto P, Guolo F, Clavio M, De Astis E, Colombo N, Grasso R, Fugazza G, Sessarego M, Lemoli RM, Gobbi M, Miglino M.

Leuk Res. 2015 Aug;39(8):866-73. doi: 10.1016/j.leukres.2015.04.011. Epub 2015 Apr 27.

PMID:
26012361
20.

WT1 gene expression lowered by IL-12 In vitro in peripheral blood mononuclear cells from patients with leukemia or myelodysplastic syndromes.

Pan L, Zhang XJ, Niu ZY, Suo XH, Zhang JY, Yang L, Liu XJ, Qiao SK, Dong ZR, Ohno R.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Jun;14(3):501-7.

PMID:
16800930

Supplemental Content

Support Center